Croda

Abstract Background/Objectives: Meloxicam (MLX) is a nonsteroidal anti-inflammatory drug (NSAID) recommended for treating acute and chronic pain in dogs, frequently...

High purity amino acids for bioprocessing and formulation Amino acids are the fundamental building blocks of proteins and play a...

Abstract Here, we report dissolution of aprepitant from three phospholipid-based amorphous solid dispersions (ASDs), namely binary ASDs containing drug and...

PRESS RELEASE 4 March 2026: Croda successfully launches new Amino Acid range BioXPro™: Croda International Plc (“Croda”) today confirms the successful...

Abstract Colorectal cancer (CRC) continues to be a foremost human health concern globally, with chemotherapy being the cornerstone of the...

In the following article, Croda International shares an exclusive conversation with one of its biologics leaders, Mo Pinto. From his...

Abstract Therapeutic agents approved for the topical treatment of dermatological diseases have diverse physicochemical properties, but they are frequently poorly...

This year DCAT Week opens its doors in New York City. From 23th to 26th March the DCAT Week 2026...

Abstract Stabilization of therapeutic protein formulations with nonionic surfactants such as Polysorbate 20 (PS20), Polysorbate 80 (PS80), or Poloxamer 188...

Abstract The toxicological evaluation of excipients plays a crucial role in the development of SEDDS. This study examined key formulation...